Member Info for Wiggly

The below is very clear to me. It would be illegal for Avacta to continue with these statements if in knowledge they were now proven false;

Regulations that affect advertising
Advertising to consumers
The Consumer Protection from Unfair Trading Regulations mean you cannot mislead or harass consumers by, for example:

including false or deceptive messages
leaving out important information
using aggressive sales techniques

https://www.gov.uk/marketing-advertising-law/regulations-that-affect-advertising

The below i

The recent addition of the word 'ONLY' is interesting though as with the Mice we know from the data that Ava6k, albeit vastly reduced, did damage the heart. Why change that key language at this late stage while in receipt of 300 days of clinical data?

Would it be legal for Avacta to claim this on their website while in receipt of data that proves otherwise ?

Howzaty,

I am as bullish as they come here but worth noting Avacta used 'similar' language prior to the trial. Below snip from the trial approval RNS:

'Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.'

I do agree though that it would be wrong to continue to publish such statements if now in the knowledge that the activation was not present in the TME.

I think what is most clear here and what most are overlooking is that only 2 weeks back Avacta guided the market VIA RNS that they remained VERY CONFIDENT about immediate future. I think we can expect a very bullish Alistair Smith on the stand next week and dependent on what is said / insinuated I think we could have fireworks.

I said earlier I think we will close the week on level.

Wouldn't want to be out of this heading into next week

I predict we will finish week where we started....

Were an absolute blood bath yesterday.

Avct will be a safe haven through these economic times. Big pharma have vision and funds that look well beyond the next few quarters (assuming recessionary) and you can be sure that Avacta licence or get bought out on good AVA6K data, therefore future funding is of no concern.

Forget all the dots (3996, DE, poster presentation, hiring of NED, move to London, comments re consistency) that clearly suggest a positive Ava6k read out and simply remember that only 2 weeks ago the Avacta BOD confirmed that they were VERY CONFIDENT ABOUT THE IMMEDIATE FUTURE.

Can you imagine AS standing on stage next week during AGM delivering a downbeat update concerning Ava6k after declaring that he was VERY CONFIDENT about the immediate future only 2 weeks ago? I certainly can't.

Don't be spooked by the trolls as news is very very close.

Agree Mr Rip, showing his true colours with that post. Funny that he re appeared following that article. Whndrum is popcorn teeth aka TW

"Even when news lands it may not be the gap up everyone expects."

I disagree. If AVCT go on to announce effective chemo with no/reduced side effects it will be explosive and AIM will have seen nothing like it before.

Ipad - the is a seller and some chunky trades going through but the MM are absorbing all and we are still + for the day. I think there must be a large buy order being worked. Seems as though games are afoot. Perhaps Blackrock transferring to blackrock!?

There has to be a strong reason for Avacta to continue to carry the cost of the enlarged (during CV) Dx division. Following the CV LFT debacle, I would have expected Avacta to trim down the Dx staffing levels however, they have in fact continued to increase...

Avacta remain confident of near term Dx revenues....

I think we could see another 1m buy after hours.

MrA,
The 4 cohorts referenced could have all been dosed at same dose level. The explanation from Fardistanhills makes sense as does AS statement.

VERY CONFIDENT!!! No BOD would make such a bold statement if in any doubt about the immediate performance (especially when read out expected within 1 month of making such a statement)

We are very confident and excited about the immediate
and long-term opportunities for the Group.

We are very confident and excited about the immediate
and long-term opportunities for the Group.

We are very confident and excited about the immediate
and long-term opportunities for the Group.

We are very confident and excited about the immediate
and long-term opportunities for the Group.

Yes, DTW - updating the market with positive guidance (on 31st May, per below) while sitting on bad AVA6k data ? Absolutely zero chance or there would be several legal claims:

Outlook (updated on May 31st, 2022)

The Board believes that the most significant near-term
value driver for the Group is the clinical data from the
Phase I study of AVA6000 expected in the middle of
2022.

We are very confident and excited about the immediate
and long-term opportunities for the Group.

Boom

I think this deserves an RNS? Perhaps we shall get one tomorrow.

I acknowledge there is some way to go however what does this now mean for the platform and forward outlook for pre|cision? The odds of success must notch up quite significantly.

Thanks for sharing Gadgie. This looks very probable that phase 1a is complete, data assessed and soft tissue sarcoma has been selected for phase 1b. All Agree ? Or am I jumping the gun

LG chem new application during may 2022